Natera wins $19 millions US cancer-detection patent case

This week, genetic testing company Natera convinced a Delaware jury that ArcherDX had infringed its cancer detection patents and won $19.3 million in damages.

Natera was able to prove to the jury that ArcherDX had infringed 3 of its patents in the field of DNA blood testing for cancer detection and monitoring.

The legal problems between Natera and ArcherDX began in 2020, and in a lawsuit filed in 2021, Natera alleged that ArcherDX had infringed its patent on non-invasive cancer testing technology that uses cell-free DNA from patients' blood cells to provide results on whether or not the patient has any type of cancer.

Archer DX attempted to defend itself in court by arguing that Natera's patents were invalid and that Natera had not provided sufficient evidence to prove that its patents had been infringed.